Lanzhou Jinglong Medical Technology Co., Ltd.

The pharmacokinetic characteristics of single (10 mg, 20 mg, 40 mg) and multiple (20 mg) doses of nafamostat mesylate were studied in healthy volunteers to understand the dynamic changes of different doses of nafamostat mesylate in the human body and its dose correlation, as well as the in vivo accumulation of multiple continuous doses, so as to provide a basis for formulating a reasonable clinical dosing regimen.

To evaluate the efficacy and safety of nafamostat mesylate injection for hemodialysis anticoagulation using heparin sodium injection as a control.